Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study
Coudert, Bruno, Pierga, Jean-Yves, Mouret-Reynier, Marie-Ange, Kerrou, Kaldoun, Ferrero, Jean-Marc, Petit, Thierry, Du, Fanny Le, Dupré, Pierre-François, Bachelot, Thomas, Gabelle, Philippe, Chauvet, Marie-Pierre, Coeffic, David, Barbe, Catherine, Prevost, Jean-Briac, Paintaud, Gilles, Thibault, Gilles, Ferhat, Abdennour, Dupin, Julien, Berriolo-Riedinger, Alina, Arnould, Laurent
Published in EClinicalMedicine (01.11.2020)
Published in EClinicalMedicine (01.11.2020)
Get full text
Journal Article
Long Terms Follow-Up of the Randomized MetaspHER Study Comparing Intravenous Versus Subcutaneous Trastuzumab in Patients’ With HER2-Positive Metastatic Breast Cancer
Pivot, Xavier, Spano, Jean-Philippe, Espie, Marc, Jouannaud, Christelle, Pottier, Valerie, Moreau, Laura, Extra, Jean Marc, Lortholary, Alain, Rivera, Pascale, Spaeth, dominique, Mouri, Zahira, Tariket, Fella, Dupin, Julien, Berthois, Aurelien, Ionescu-Goga, Miruna, Ferhat, Abdennour, Cottu, Paul, Gligorov, Joseph
Published in Clinical breast cancer (01.10.2023)
Published in Clinical breast cancer (01.10.2023)
Get full text
Journal Article